ID   BAIP2_HUMAN             Reviewed;         552 AA.
AC   Q9UQB8; O43858; Q53HB1; Q86WC1; Q8N5C0; Q96CR7; Q9UBR3; Q9UQ43;
DT   30-AUG-2005, integrated into UniProtKB/Swiss-Prot.
DT   01-MAY-2000, sequence version 1.
DT   28-JUN-2023, entry version 200.
DE   RecName: Full=Brain-specific angiogenesis inhibitor 1-associated protein 2;
DE            Short=BAI-associated protein 2;
DE            Short=BAI1-associated protein 2;
DE            Short=Protein BAP2;
DE   AltName: Full=Fas ligand-associated factor 3;
DE            Short=FLAF3;
DE   AltName: Full=Insulin receptor substrate p53/p58;
DE            Short=IRS-58;
DE            Short=IRSp53/58;
DE   AltName: Full=Insulin receptor substrate protein of 53 kDa;
DE            Short=IRSp53;
DE            Short=Insulin receptor substrate p53;
GN   Name=BAIAP2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 4 AND 5), INTERACTION WITH ADGRB1,
RP   SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.
RC   TISSUE=Fetal brain;
RX   PubMed=10343108; DOI=10.1159/000015219;
RA   Oda K., Shiratsuchi T., Nishimori H., Inazawa J., Yoshikawa H.,
RA   Taketani Y., Nakamura Y., Tokino T.;
RT   "Identification of BAIAP2 (BAI-associated protein 2), a novel human
RT   homologue of hamster IRSp53, whose SH3 domain interacts with the
RT   cytoplasmic domain of BAI1.";
RL   Cytogenet. Cell Genet. 84:75-82(1999).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 4), PHOSPHORYLATION AT TYROSINE
RP   RESIDUES, SUBCELLULAR LOCATION, INTERACTION WITH ATN1, AND TISSUE
RP   SPECIFICITY.
RC   TISSUE=Fetal brain;
RX   PubMed=10332026; DOI=10.1093/hmg/8.6.947;
RA   Okamura-Oho Y., Miyashita T., Ohmi K., Yamada M.;
RT   "Dentatorubral-pallidoluysian atrophy protein interacts through a proline-
RT   rich region near polyglutamine with the SH3 domain of an insulin receptor
RT   tyrosine kinase substrate.";
RL   Hum. Mol. Genet. 8:947-957(1999).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORMS 1; 2; 4 AND 5).
RX   PubMed=12884081; DOI=10.1007/s10038-003-0047-x;
RA   Miyahara A., Okumura-Oho Y., Miyashita T., Hoshika A., Yamada M.;
RT   "Genomic structure and alternative splicing of the insulin receptor
RT   tyrosine kinase substrate of 53-kDa protein.";
RL   J. Hum. Genet. 48:410-414(2003).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 6).
RC   TISSUE=Brain;
RA   Suzuki Y., Sugano S., Totoki Y., Toyoda A., Takeda T., Sakaki Y.,
RA   Tanaka A., Yokoyama S.;
RL   Submitted (APR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 3; 4 AND 6).
RC   TISSUE=Brain, and Duodenum;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1-328.
RC   TISSUE=Placenta;
RA   Hachiya T., Kobayasi A., Touji S., Tamai K.;
RT   "A Fas-ligand associated factor 3, FLAF3, potentiates Fas-ligand
RT   stability.";
RL   Submitted (SEP-1996) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   FUNCTION, AND INTERACTION WITH RAC1; CDC42; WASF1 AND WASF2.
RX   PubMed=11130076; DOI=10.1038/35047107;
RA   Miki H., Yamaguchi H., Suetsugu S., Takenawa T.;
RT   "IRSp53 is an essential intermediate between Rac and WAVE in the regulation
RT   of membrane ruffling.";
RL   Nature 408:732-735(2000).
RN   [8]
RP   FUNCTION, INTERACTION WITH CDC42 AND ENAH, AND MUTAGENESIS OF PHE-427 AND
RP   PRO-428.
RX   PubMed=11696321; DOI=10.1016/s0960-9822(01)00506-1;
RA   Krugmann S., Jordens I., Gevaert K., Driessens M., Vandekerckhove J.,
RA   Hall A.;
RT   "Cdc42 induces filopodia by promoting the formation of an IRSp53:Mena
RT   complex.";
RL   Curr. Biol. 11:1645-1655(2001).
RN   [9]
RP   INTERACTION WITH CDC42, MUTAGENESIS OF ILE-267, AND TISSUE SPECIFICITY.
RX   PubMed=11157984; DOI=10.1083/jcb.152.3.579;
RA   Govind S., Kozma R., Monfries C., Lim L., Ahmed S.;
RT   "Cdc42Hs facilitates cytoskeletal reorganization and neurite outgrowth by
RT   localizing the 58-kD insulin receptor substrate to filamentous actin.";
RL   J. Cell Biol. 152:579-594(2001).
RN   [10]
RP   INTERACTION WITH SHANK1; SHANK2; SHANK3 AND CDC42, AND SUBCELLULAR
RP   LOCATION.
RX   PubMed=12504591; DOI=10.1006/mcne.2002.1201;
RA   Soltau M., Richter D., Kreienkamp H.-J.;
RT   "The insulin receptor substrate IRSp53 links postsynaptic shank1 to the
RT   small G-protein cdc42.";
RL   Mol. Cell. Neurosci. 21:575-583(2002).
RN   [11]
RP   INTERACTION WITH EPS8, AND SUBCELLULAR LOCATION.
RX   PubMed=15289329; DOI=10.1158/0008-5472.can-04-0327;
RA   Funato Y., Terabayashi T., Suenaga N., Seiki M., Takenawa T., Miki H.;
RT   "IRSp53/Eps8 complex is important for positive regulation of Rac and cancer
RT   cell motility/invasiveness.";
RL   Cancer Res. 64:5237-5244(2004).
RN   [12]
RP   DOMAIN, AND FUNCTION.
RX   PubMed=14752106; DOI=10.1074/jbc.m309408200;
RA   Yamagishi A., Masuda M., Ohki T., Onishi H., Mochizuki N.;
RT   "A novel actin bundling/filopodium-forming domain conserved in insulin
RT   receptor tyrosine kinase substrate p53 and missing in metastasis protein.";
RL   J. Biol. Chem. 279:14929-14936(2004).
RN   [13]
RP   FUNCTION, INTERACTION WITH EPS8, AND MUTAGENESIS OF TRP-413.
RX   PubMed=17115031; DOI=10.1038/ncb1502;
RA   Disanza A., Mantoani S., Hertzog M., Gerboth S., Frittoli E., Steffen A.,
RA   Berhoerster K., Kreienkamp H.J., Milanesi F., Di Fiore P.P., Ciliberto A.,
RA   Stradal T.E., Scita G.;
RT   "Regulation of cell shape by Cdc42 is mediated by the synergic actin-
RT   bundling activity of the Eps8-IRSp53 complex.";
RL   Nat. Cell Biol. 8:1337-1347(2006).
RN   [14]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-296; SER-323; SER-325;
RP   SER-346 AND SER-366, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [15]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in a
RT   refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [16]
RP   INTERACTION WITH E.COLI EFFECTOR PROTEIN ESPF(U) AND WITH E.COLI INTIMIN
RP   RECEPTOR TIR.
RX   PubMed=19286134; DOI=10.1016/j.chom.2009.02.003;
RA   Weiss S.M., Ladwein M., Schmidt D., Ehinger J., Lommel S., Stading K.,
RA   Beutling U., Disanza A., Frank R., Jansch L., Scita G., Gunzer F.,
RA   Rottner K., Stradal T.E.;
RT   "IRSp53 links the enterohemorrhagic E. coli effectors Tir and EspFU for
RT   actin pedestal formation.";
RL   Cell Host Microbe 5:244-258(2009).
RN   [17]
RP   FUNCTION, INTERACTION WITH E.COLI EFFECTOR PROTEIN ESPF(U), AND SUBCELLULAR
RP   LOCATION.
RX   PubMed=19366662; DOI=10.1073/pnas.0809131106;
RA   Vingadassalom D., Kazlauskas A., Skehan B., Cheng H.C., Magoun L.,
RA   Robbins D., Rosen M.K., Saksela K., Leong J.M.;
RT   "Insulin receptor tyrosine kinase substrate links the E. coli O157:H7 actin
RT   assembly effectors Tir and EspF(U) during pedestal formation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 106:6754-6759(2009).
RN   [18]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-340, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [19]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [20]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-454, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T.,
RA   Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.;
RT   "System-wide temporal characterization of the proteome and phosphoproteome
RT   of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [21]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-261; SER-325; SER-336;
RP   THR-340; THR-360; SER-366 AND SER-384, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [22]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-366, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [23]
RP   X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 1-250, AND MUTAGENESIS OF LYS-142;
RP   LYS-143; LYS-146 AND LYS-147.
RX   PubMed=15635447; DOI=10.1038/sj.emboj.7600535;
RA   Millard T.H., Bompard G., Heung M.Y., Dafforn T.R., Scott D.J.,
RA   Machesky L.M., Fuetterer K.;
RT   "Structural basis of filopodia formation induced by the IRSp53/MIM homology
RT   domain of human IRSp53.";
RL   EMBO J. 24:240-250(2005).
RN   [24]
RP   X-RAY CRYSTALLOGRAPHY (2.63 ANGSTROMS) OF 1-228.
RG   RIKEN structural genomics initiative (RSGI);
RT   "Crystal structure of RCB domain of IRSP53.";
RL   Submitted (JUN-2005) to the PDB data bank.
CC   -!- FUNCTION: Adapter protein that links membrane-bound small G-proteins to
CC       cytoplasmic effector proteins. Necessary for CDC42-mediated
CC       reorganization of the actin cytoskeleton and for RAC1-mediated membrane
CC       ruffling. Involved in the regulation of the actin cytoskeleton by WASF
CC       family members and the Arp2/3 complex. Plays a role in neurite growth.
CC       Acts syngeristically with ENAH to promote filipodia formation. Plays a
CC       role in the reorganization of the actin cytoskeleton in response to
CC       bacterial infection. Participates in actin bundling when associated
CC       with EPS8, promoting filopodial protrusions.
CC       {ECO:0000269|PubMed:11130076, ECO:0000269|PubMed:11696321,
CC       ECO:0000269|PubMed:14752106, ECO:0000269|PubMed:17115031,
CC       ECO:0000269|PubMed:19366662}.
CC   -!- SUBUNIT: Homodimer. Interacts with CDC42 and RAC1 that have been
CC       activated by GTP binding. Interacts with ATN1, ADGRB1, EPS8, SHANK1,
CC       SHANK2, SHANK3, WASF1 and WASF2. Interacts with ENAH after recruitment
CC       of CDC42. Interacts with TIAM1 and DIAPH1 (By similarity). Interacts
CC       (via SH3 domain) with E.coli effector protein EspF(U) (via PXXP
CC       motifs). Interacts with E.coli intimin receptor Tir. {ECO:0000250,
CC       ECO:0000269|PubMed:10332026, ECO:0000269|PubMed:10343108,
CC       ECO:0000269|PubMed:11130076, ECO:0000269|PubMed:11157984,
CC       ECO:0000269|PubMed:11696321, ECO:0000269|PubMed:12504591,
CC       ECO:0000269|PubMed:15289329, ECO:0000269|PubMed:17115031,
CC       ECO:0000269|PubMed:19286134, ECO:0000269|PubMed:19366662}.
CC   -!- INTERACTION:
CC       Q9UQB8; Q9UQB8: BAIAP2; NbExp=5; IntAct=EBI-525456, EBI-525456;
CC       Q9UQB8; Q9UFG5: C19orf25; NbExp=3; IntAct=EBI-525456, EBI-741214;
CC       Q9UQB8; P60953: CDC42; NbExp=2; IntAct=EBI-525456, EBI-81752;
CC       Q9UQB8; P60953-2: CDC42; NbExp=2; IntAct=EBI-525456, EBI-287394;
CC       Q9UQB8; P00533: EGFR; NbExp=4; IntAct=EBI-525456, EBI-297353;
CC       Q9UQB8; Q12929: EPS8; NbExp=10; IntAct=EBI-525456, EBI-375576;
CC       Q9UQB8; Q14678: KANK1; NbExp=6; IntAct=EBI-525456, EBI-2556221;
CC       Q9UQB8; Q9NZQ3: NCKIPSD; NbExp=2; IntAct=EBI-525456, EBI-745080;
CC       Q9UQB8; Q9NZ81: PRR13; NbExp=3; IntAct=EBI-525456, EBI-740924;
CC       Q9UQB8; P63000: RAC1; NbExp=4; IntAct=EBI-525456, EBI-413628;
CC       Q9UQB8; Q15427: SF3B4; NbExp=3; IntAct=EBI-525456, EBI-348469;
CC       Q9UQB8; Q13625-3: TP53BP2; NbExp=3; IntAct=EBI-525456, EBI-10175039;
CC       Q9UQB8; P63104: YWHAZ; NbExp=3; IntAct=EBI-525456, EBI-347088;
CC       Q9UQB8; Q8CFN2: Cdc42; Xeno; NbExp=2; IntAct=EBI-525456, EBI-7023929;
CC       Q9UQB8; Q03173: Enah; Xeno; NbExp=3; IntAct=EBI-525456, EBI-6083294;
CC       Q9UQB8; Q08509: Eps8; Xeno; NbExp=8; IntAct=EBI-525456, EBI-375596;
CC       Q9UQB8; Q7DB77: tir; Xeno; NbExp=3; IntAct=EBI-525456, EBI-6480811;
CC       Q9UQB8-3; Q86V38: ATN1; NbExp=3; IntAct=EBI-9091996, EBI-11954292;
CC       Q9UQB8-3; P42858: HTT; NbExp=18; IntAct=EBI-9091996, EBI-466029;
CC       Q9UQB8-3; Q92876: KLK6; NbExp=3; IntAct=EBI-9091996, EBI-2432309;
CC       Q9UQB8-3; Q7Z412: PEX26; NbExp=3; IntAct=EBI-9091996, EBI-752057;
CC       Q9UQB8-3; D3DTS7: PMP22; NbExp=3; IntAct=EBI-9091996, EBI-25882629;
CC       Q9UQB8-3; Q8IUH5: ZDHHC17; NbExp=3; IntAct=EBI-9091996, EBI-524753;
CC       Q9UQB8-4; Q9UQB8-4: BAIAP2; NbExp=4; IntAct=EBI-6174091, EBI-6174091;
CC       Q9UQB8-4; P60953: CDC42; NbExp=4; IntAct=EBI-6174091, EBI-81752;
CC       Q9UQB8-4; P60953-2: CDC42; NbExp=5; IntAct=EBI-6174091, EBI-287394;
CC       Q9UQB8-4; Q12929: EPS8; NbExp=4; IntAct=EBI-6174091, EBI-375576;
CC       Q9UQB8-4; Q14678-2: KANK1; NbExp=4; IntAct=EBI-6174091, EBI-6173812;
CC       Q9UQB8-4; P50552: VASP; NbExp=6; IntAct=EBI-6174091, EBI-748201;
CC       Q9UQB8-4; Q9Y6W5: WASF2; NbExp=5; IntAct=EBI-6174091, EBI-4290615;
CC       Q9UQB8-4; B7UM99: tir; Xeno; NbExp=3; IntAct=EBI-6174091, EBI-2504426;
CC       Q9UQB8-4; Q7DB77: tir; Xeno; NbExp=5; IntAct=EBI-6174091, EBI-6480811;
CC       Q9UQB8-6; Q86V38: ATN1; NbExp=3; IntAct=EBI-9092016, EBI-11954292;
CC       Q9UQB8-6; P54253: ATXN1; NbExp=6; IntAct=EBI-9092016, EBI-930964;
CC       Q9UQB8-6; Q9UHR4: BAIAP2L1; NbExp=3; IntAct=EBI-9092016, EBI-2483278;
CC       Q9UQB8-6; P28329-3: CHAT; NbExp=3; IntAct=EBI-9092016, EBI-25837549;
CC       Q9UQB8-6; Q9Y2V7: COG6; NbExp=3; IntAct=EBI-9092016, EBI-3866319;
CC       Q9UQB8-6; P02489: CRYAA; NbExp=3; IntAct=EBI-9092016, EBI-6875961;
CC       Q9UQB8-6; P50570-2: DNM2; NbExp=3; IntAct=EBI-9092016, EBI-10968534;
CC       Q9UQB8-6; P22607: FGFR3; NbExp=3; IntAct=EBI-9092016, EBI-348399;
CC       Q9UQB8-6; Q8TB36: GDAP1; NbExp=3; IntAct=EBI-9092016, EBI-11110431;
CC       Q9UQB8-6; P14136: GFAP; NbExp=3; IntAct=EBI-9092016, EBI-744302;
CC       Q9UQB8-6; P13378: HOXD8; NbExp=3; IntAct=EBI-9092016, EBI-7098661;
CC       Q9UQB8-6; P42858: HTT; NbExp=18; IntAct=EBI-9092016, EBI-466029;
CC       Q9UQB8-6; Q8WXH2: JPH3; NbExp=3; IntAct=EBI-9092016, EBI-1055254;
CC       Q9UQB8-6; O60333-2: KIF1B; NbExp=3; IntAct=EBI-9092016, EBI-10975473;
CC       Q9UQB8-6; Q92876: KLK6; NbExp=3; IntAct=EBI-9092016, EBI-2432309;
CC       Q9UQB8-6; Q15428: SF3A2; NbExp=3; IntAct=EBI-9092016, EBI-2462271;
CC       Q9UQB8-6; Q9UPX8-4: SHANK2; NbExp=3; IntAct=EBI-9092016, EBI-11959011;
CC       Q9UQB8-6; Q99593: TBX5; NbExp=3; IntAct=EBI-9092016, EBI-297043;
CC       Q9UQB8-6; Q05BL1: TP53BP2; NbExp=3; IntAct=EBI-9092016, EBI-11952721;
CC       Q9UQB8-6; Q9UMX0: UBQLN1; NbExp=3; IntAct=EBI-9092016, EBI-741480;
CC       Q9UQB8-6; O76024: WFS1; NbExp=3; IntAct=EBI-9092016, EBI-720609;
CC       Q9UQB8-6; Q8IUH5: ZDHHC17; NbExp=2; IntAct=EBI-9092016, EBI-524753;
CC       Q9UQB8-6; Q9Y649; NbExp=3; IntAct=EBI-9092016, EBI-25900580;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm. Membrane; Peripheral membrane protein.
CC       Cell projection, filopodium. Cell projection, ruffle. Cytoplasm,
CC       cytoskeleton. Note=Detected throughout the cytoplasm in the absence of
CC       specific binding partners. Detected in filopodia and close to membrane
CC       ruffles. Recruited to actin pedestals that are formed upon infection by
CC       bacteria at bacterial attachment sites.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=6;
CC       Name=1; Synonyms=IRSp53(L);
CC         IsoId=Q9UQB8-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q9UQB8-2; Sequence=VSP_015506;
CC       Name=3;
CC         IsoId=Q9UQB8-3; Sequence=VSP_015505;
CC       Name=4; Synonyms=BAIAP2-alpha;
CC         IsoId=Q9UQB8-4; Sequence=VSP_015503;
CC       Name=5; Synonyms=BAIAP2-beta;
CC         IsoId=Q9UQB8-5; Sequence=VSP_015504;
CC       Name=6;
CC         IsoId=Q9UQB8-6; Sequence=VSP_015502, VSP_015503;
CC   -!- TISSUE SPECIFICITY: Isoform 1 and isoform 4 are expressed almost
CC       exclusively in brain. Isoform 4 is barely detectable in placenta,
CC       prostate and testis. A short isoform is ubiquitous, with the highest
CC       expression in liver, prostate, testis and placenta.
CC       {ECO:0000269|PubMed:10332026, ECO:0000269|PubMed:10343108,
CC       ECO:0000269|PubMed:11157984}.
CC   -!- DOMAIN: The IMD domain forms a coiled coil. The isolated domain can
CC       induce actin bundling and filopodia formation. In the absence of G-
CC       proteins intramolecular interaction between the IMD and the SH3 domain
CC       gives rise to an auto-inhibited state of the protein. Interaction of
CC       the IMD with RAC1 or CDC42 leads to activation.
CC       {ECO:0000269|PubMed:14752106}.
CC   -!- DOMAIN: The SH3 domain interacts with ATN1, ADGRB1, WASF1, WASF2,
CC       SHANK1, DIAPH1 and ENAH. {ECO:0000269|PubMed:14752106}.
CC   -!- PTM: Phosphorylated on tyrosine residues by INSR in response to insulin
CC       treatment. {ECO:0000269|PubMed:10332026}.
CC   -!- CAUTION: It is uncertain whether Met-1 or Met-59 is the initiator.
CC       {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AB015019; BAA36586.1; -; mRNA.
DR   EMBL; AB015020; BAA36587.1; -; mRNA.
DR   EMBL; AB017119; BAA74773.1; -; mRNA.
DR   EMBL; AB017120; BAA74774.1; -; mRNA.
DR   EMBL; AB104726; BAC57945.1; -; Genomic_DNA.
DR   EMBL; AB104726; BAC57946.1; -; Genomic_DNA.
DR   EMBL; AB104726; BAC57947.1; -; Genomic_DNA.
DR   EMBL; AB104726; BAC57948.1; -; Genomic_DNA.
DR   EMBL; AK222670; BAD96390.1; -; mRNA.
DR   EMBL; BC014020; AAH14020.1; -; mRNA.
DR   EMBL; BC032559; AAH32559.1; -; mRNA.
DR   EMBL; U70669; AAB93497.1; -; mRNA.
DR   CCDS; CCDS11775.1; -. [Q9UQB8-1]
DR   CCDS; CCDS11776.1; -. [Q9UQB8-5]
DR   CCDS; CCDS11777.1; -. [Q9UQB8-4]
DR   CCDS; CCDS45806.1; -. [Q9UQB8-2]
DR   RefSeq; NP_001138360.1; NM_001144888.1. [Q9UQB8-2]
DR   RefSeq; NP_006331.1; NM_006340.2. [Q9UQB8-5]
DR   RefSeq; NP_059344.1; NM_017450.2. [Q9UQB8-4]
DR   RefSeq; NP_059345.1; NM_017451.2. [Q9UQB8-1]
DR   RefSeq; XP_005257005.1; XM_005256948.3.
DR   PDB; 1WDZ; X-ray; 2.63 A; A/B=1-228.
DR   PDB; 1Y2O; X-ray; 2.20 A; A/B=1-250.
DR   PDB; 2YKT; X-ray; 2.11 A; A=1-250.
DR   PDB; 3RNJ; X-ray; 1.50 A; A=375-436.
DR   PDB; 4JS0; X-ray; 1.90 A; B=260-291.
DR   PDB; 6BCR; X-ray; 1.99 A; C/D/G/H=333-346.
DR   PDB; 6BCY; X-ray; 2.30 A; C/D/G/H=354-366.
DR   PDB; 6BD1; X-ray; 2.35 A; C/D/G/H=360-373.
DR   PDB; 6BD2; X-ray; 2.90 A; C=335-372.
DR   PDB; 6BQT; X-ray; 2.80 A; C/F/I/L=335-366.
DR   PDB; 6ZEG; X-ray; 1.09 A; A/B=448-464.
DR   PDB; 6ZEI; X-ray; 1.39 A; A/B=448-464.
DR   PDBsum; 1WDZ; -.
DR   PDBsum; 1Y2O; -.
DR   PDBsum; 2YKT; -.
DR   PDBsum; 3RNJ; -.
DR   PDBsum; 4JS0; -.
DR   PDBsum; 6BCR; -.
DR   PDBsum; 6BCY; -.
DR   PDBsum; 6BD1; -.
DR   PDBsum; 6BD2; -.
DR   PDBsum; 6BQT; -.
DR   PDBsum; 6ZEG; -.
DR   PDBsum; 6ZEI; -.
DR   AlphaFoldDB; Q9UQB8; -.
DR   SMR; Q9UQB8; -.
DR   BioGRID; 115721; 184.
DR   DIP; DIP-29272N; -.
DR   IntAct; Q9UQB8; 111.
DR   MINT; Q9UQB8; -.
DR   STRING; 9606.ENSP00000316338; -.
DR   GlyGen; Q9UQB8; 1 site, 1 O-linked glycan (1 site).
DR   iPTMnet; Q9UQB8; -.
DR   PhosphoSitePlus; Q9UQB8; -.
DR   SwissPalm; Q9UQB8; -.
DR   BioMuta; BAIAP2; -.
DR   DMDM; 73917636; -.
DR   UCD-2DPAGE; Q9UQB8; -.
DR   EPD; Q9UQB8; -.
DR   jPOST; Q9UQB8; -.
DR   MassIVE; Q9UQB8; -.
DR   MaxQB; Q9UQB8; -.
DR   PaxDb; Q9UQB8; -.
DR   PeptideAtlas; Q9UQB8; -.
DR   ProteomicsDB; 85532; -. [Q9UQB8-1]
DR   ProteomicsDB; 85533; -. [Q9UQB8-2]
DR   ProteomicsDB; 85534; -. [Q9UQB8-3]
DR   ProteomicsDB; 85535; -. [Q9UQB8-4]
DR   ProteomicsDB; 85536; -. [Q9UQB8-5]
DR   ProteomicsDB; 85537; -. [Q9UQB8-6]
DR   ABCD; Q9UQB8; 11 sequenced antibodies.
DR   Antibodypedia; 19790; 598 antibodies from 38 providers.
DR   DNASU; 10458; -.
DR   Ensembl; ENST00000321280.11; ENSP00000315685.7; ENSG00000175866.16. [Q9UQB8-4]
DR   Ensembl; ENST00000321300.10; ENSP00000316338.6; ENSG00000175866.16. [Q9UQB8-1]
DR   Ensembl; ENST00000428708.7; ENSP00000401022.2; ENSG00000175866.16. [Q9UQB8-2]
DR   Ensembl; ENST00000435091.7; ENSP00000413069.3; ENSG00000175866.16. [Q9UQB8-5]
DR   Ensembl; ENST00000575712.5; ENSP00000458964.1; ENSG00000175866.16. [Q9UQB8-3]
DR   GeneID; 10458; -.
DR   KEGG; hsa:10458; -.
DR   MANE-Select; ENST00000428708.7; ENSP00000401022.2; NM_001144888.2; NP_001138360.1. [Q9UQB8-2]
DR   UCSC; uc002jyz.5; human. [Q9UQB8-1]
DR   AGR; HGNC:947; -.
DR   CTD; 10458; -.
DR   DisGeNET; 10458; -.
DR   GeneCards; BAIAP2; -.
DR   HGNC; HGNC:947; BAIAP2.
DR   HPA; ENSG00000175866; Low tissue specificity.
DR   MIM; 605475; gene.
DR   neXtProt; NX_Q9UQB8; -.
DR   OpenTargets; ENSG00000175866; -.
DR   PharmGKB; PA25251; -.
DR   VEuPathDB; HostDB:ENSG00000175866; -.
DR   eggNOG; ENOG502QUM6; Eukaryota.
DR   GeneTree; ENSGT00940000153560; -.
DR   HOGENOM; CLU_025877_0_1_1; -.
DR   InParanoid; Q9UQB8; -.
DR   OMA; KNSYATX; -.
DR   OrthoDB; 3059844at2759; -.
DR   PhylomeDB; Q9UQB8; -.
DR   TreeFam; TF325648; -.
DR   PathwayCommons; Q9UQB8; -.
DR   Reactome; R-HSA-2029482; Regulation of actin dynamics for phagocytic cup formation.
DR   Reactome; R-HSA-4420097; VEGFA-VEGFR2 Pathway.
DR   Reactome; R-HSA-5663213; RHO GTPases Activate WASPs and WAVEs.
DR   Reactome; R-HSA-9013148; CDC42 GTPase cycle.
DR   Reactome; R-HSA-9013149; RAC1 GTPase cycle.
DR   Reactome; R-HSA-9013423; RAC3 GTPase cycle.
DR   Reactome; R-HSA-9664422; FCGR3A-mediated phagocytosis.
DR   SignaLink; Q9UQB8; -.
DR   SIGNOR; Q9UQB8; -.
DR   BioGRID-ORCS; 10458; 24 hits in 1168 CRISPR screens.
DR   ChiTaRS; BAIAP2; human.
DR   EvolutionaryTrace; Q9UQB8; -.
DR   GeneWiki; BAIAP2; -.
DR   GenomeRNAi; 10458; -.
DR   Pharos; Q9UQB8; Tbio.
DR   PRO; PR:Q9UQB8; -.
DR   Proteomes; UP000005640; Chromosome 17.
DR   RNAct; Q9UQB8; protein.
DR   Bgee; ENSG00000175866; Expressed in Brodmann (1909) area 10 and 170 other tissues.
DR   ExpressionAtlas; Q9UQB8; baseline and differential.
DR   Genevisible; Q9UQB8; HS.
DR   GO; GO:0005912; C:adherens junction; HDA:BHF-UCL.
DR   GO; GO:0005737; C:cytoplasm; TAS:ProtInc.
DR   GO; GO:0005829; C:cytosol; IDA:UniProtKB.
DR   GO; GO:0043198; C:dendritic shaft; IEA:Ensembl.
DR   GO; GO:0061846; C:dendritic spine cytoplasm; IEA:Ensembl.
DR   GO; GO:0060076; C:excitatory synapse; IEA:Ensembl.
DR   GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB.
DR   GO; GO:0030175; C:filopodium; IEA:UniProtKB-SubCell.
DR   GO; GO:0098978; C:glutamatergic synapse; IEA:Ensembl.
DR   GO; GO:0005794; C:Golgi apparatus; IEA:Ensembl.
DR   GO; GO:0030027; C:lamellipodium; IEA:Ensembl.
DR   GO; GO:0005874; C:microtubule; IEA:Ensembl.
DR   GO; GO:0061845; C:neuron projection branch point; IEA:Ensembl.
DR   GO; GO:0044306; C:neuron projection terminus; IEA:Ensembl.
DR   GO; GO:0043025; C:neuronal cell body; IEA:Ensembl.
DR   GO; GO:0005654; C:nucleoplasm; IBA:GO_Central.
DR   GO; GO:0005886; C:plasma membrane; IDA:HPA.
DR   GO; GO:0099524; C:postsynaptic cytosol; IEA:Ensembl.
DR   GO; GO:0099092; C:postsynaptic density, intracellular component; IEA:Ensembl.
DR   GO; GO:0099523; C:presynaptic cytosol; IEA:Ensembl.
DR   GO; GO:0005791; C:rough endoplasmic reticulum; IEA:Ensembl.
DR   GO; GO:0001726; C:ruffle; IEA:UniProtKB-SubCell.
DR   GO; GO:0098685; C:Schaffer collateral - CA1 synapse; IEA:Ensembl.
DR   GO; GO:0030141; C:secretory granule; IEA:Ensembl.
DR   GO; GO:0097060; C:synaptic membrane; IEA:Ensembl.
DR   GO; GO:0098641; F:cadherin binding involved in cell-cell adhesion; HDA:BHF-UCL.
DR   GO; GO:0008093; F:cytoskeletal anchor activity; TAS:ProtInc.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0030165; F:PDZ domain binding; IEA:Ensembl.
DR   GO; GO:0070064; F:proline-rich region binding; IDA:UniProtKB.
DR   GO; GO:0097110; F:scaffold protein binding; IEA:Ensembl.
DR   GO; GO:0001221; F:transcription coregulator binding; IEA:Ensembl.
DR   GO; GO:0051764; P:actin crosslink formation; ISS:UniProtKB.
DR   GO; GO:0051017; P:actin filament bundle assembly; ISS:UniProtKB.
DR   GO; GO:0007409; P:axonogenesis; TAS:ProtInc.
DR   GO; GO:0007420; P:brain development; IEA:Ensembl.
DR   GO; GO:0071364; P:cellular response to epidermal growth factor stimulus; IEA:Ensembl.
DR   GO; GO:1905232; P:cellular response to L-glutamate; IEA:Ensembl.
DR   GO; GO:0016358; P:dendrite development; IEA:Ensembl.
DR   GO; GO:0008286; P:insulin receptor signaling pathway; TAS:ProtInc.
DR   GO; GO:0007009; P:plasma membrane organization; IEA:InterPro.
DR   GO; GO:2000251; P:positive regulation of actin cytoskeleton reorganization; IBA:GO_Central.
DR   GO; GO:0030838; P:positive regulation of actin filament polymerization; IBA:GO_Central.
DR   GO; GO:0061003; P:positive regulation of dendritic spine morphogenesis; IEA:Ensembl.
DR   GO; GO:2000463; P:positive regulation of excitatory postsynaptic potential; IEA:Ensembl.
DR   GO; GO:0035418; P:protein localization to synapse; IEA:Ensembl.
DR   GO; GO:0032956; P:regulation of actin cytoskeleton organization; IMP:UniProtKB.
DR   GO; GO:0008360; P:regulation of cell shape; ISS:UniProtKB.
DR   GO; GO:1905274; P:regulation of modification of postsynaptic actin cytoskeleton; IEA:Ensembl.
DR   GO; GO:0048167; P:regulation of synaptic plasticity; IEA:Ensembl.
DR   CDD; cd07646; I-BAR_IMD_IRSp53; 1.
DR   CDD; cd11915; SH3_Irsp53; 1.
DR   Gene3D; 1.20.1270.60; Arfaptin homology (AH) domain/BAR domain; 1.
DR   Gene3D; 2.30.30.40; SH3 Domains; 1.
DR   InterPro; IPR027267; AH/BAR_dom_sf.
DR   InterPro; IPR013606; I-BAR_dom.
DR   InterPro; IPR027681; IRSp53/IRTKS/Pinkbar.
DR   InterPro; IPR030128; IRSp53_I-BAR_dom.
DR   InterPro; IPR035594; Irsp53_SH3.
DR   InterPro; IPR036028; SH3-like_dom_sf.
DR   InterPro; IPR001452; SH3_domain.
DR   PANTHER; PTHR14206; BRAIN-SPECIFIC ANGIOGENESIS INHIBITOR 1-ASSOCIATED PROTEIN 2; 1.
DR   PANTHER; PTHR14206:SF3; BRAIN-SPECIFIC ANGIOGENESIS INHIBITOR 1-ASSOCIATED PROTEIN 2; 1.
DR   Pfam; PF08397; IMD; 1.
DR   Pfam; PF07653; SH3_2; 1.
DR   SMART; SM00326; SH3; 1.
DR   SUPFAM; SSF103657; BAR/IMD domain-like; 1.
DR   SUPFAM; SSF50044; SH3-domain; 1.
DR   PROSITE; PS51338; IMD; 1.
DR   PROSITE; PS50002; SH3; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Cell projection; Coiled coil;
KW   Cytoplasm; Cytoskeleton; Membrane; Phosphoprotein; Reference proteome;
KW   SH3 domain.
FT   CHAIN           1..552
FT                   /note="Brain-specific angiogenesis inhibitor 1-associated
FT                   protein 2"
FT                   /id="PRO_0000064816"
FT   DOMAIN          1..250
FT                   /note="IMD"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00668"
FT   DOMAIN          374..437
FT                   /note="SH3"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00192"
FT   REGION          295..369
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          447..466
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          525..552
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COILED          132..153
FT                   /evidence="ECO:0000255"
FT   COMPBIAS        322..367
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOD_RES         261
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         296
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:18669648"
FT   MOD_RES         323
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648"
FT   MOD_RES         325
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         336
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         340
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:20068231,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         346
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648"
FT   MOD_RES         360
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         366
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:23186163, ECO:0007744|PubMed:24275569"
FT   MOD_RES         384
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         395
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q8BKX1"
FT   MOD_RES         454
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:21406692"
FT   VAR_SEQ         356
FT                   /note="T -> TA (in isoform 6)"
FT                   /evidence="ECO:0000303|PubMed:15489334, ECO:0000303|Ref.4"
FT                   /id="VSP_015502"
FT   VAR_SEQ         512..552
FT                   /note="RNPFAHVQLKPTVTNDRCDLSAQGPEGREHGDGSARTLAGR -> SGSGTLV
FT                   STV (in isoform 4 and isoform 6)"
FT                   /evidence="ECO:0000303|PubMed:10332026,
FT                   ECO:0000303|PubMed:10343108, ECO:0000303|PubMed:15489334,
FT                   ECO:0000303|Ref.4"
FT                   /id="VSP_015503"
FT   VAR_SEQ         512..552
FT                   /note="RNPFAHVQLKPTVTNDRCDLSAQGPEGREHGDGSARTLAGR -> SADVEVA
FT                   RF (in isoform 5)"
FT                   /evidence="ECO:0000303|PubMed:10343108"
FT                   /id="VSP_015504"
FT   VAR_SEQ         513..552
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_015505"
FT   VAR_SEQ         529..552
FT                   /note="CDLSAQGPEGREHGDGSARTLAGR -> SAPLLS (in isoform 2)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_015506"
FT   VARIANT         519
FT                   /note="Q -> R (in dbSNP:rs4969391)"
FT                   /id="VAR_050686"
FT   MUTAGEN         142
FT                   /note="K->E: Abolishes actin-bundling and filopodia
FT                   formation; when associated with E-143; E-146 and E147."
FT                   /evidence="ECO:0000269|PubMed:15635447"
FT   MUTAGEN         143
FT                   /note="K->E: Abolishes actin-bundling and filopodia
FT                   formation; when associated with E-142; E-146 and E147."
FT                   /evidence="ECO:0000269|PubMed:15635447"
FT   MUTAGEN         146
FT                   /note="K->E: Abolishes actin-bundling and filopodia
FT                   formation; when associated with E-142; E-143 and E147."
FT                   /evidence="ECO:0000269|PubMed:15635447"
FT   MUTAGEN         147
FT                   /note="K->E: Abolishes actin-bundling and filopodia
FT                   formation; when associated with E-142; E-143 and E146."
FT                   /evidence="ECO:0000269|PubMed:15635447"
FT   MUTAGEN         267
FT                   /note="I->N: Loss of interaction with CDC42. Loss of
FT                   stimulation of neurite growth."
FT                   /evidence="ECO:0000269|PubMed:11157984"
FT   MUTAGEN         413
FT                   /note="W->G: Impairs the SH3 domain and abolishes the
FT                   interaction with EPS8."
FT                   /evidence="ECO:0000269|PubMed:17115031"
FT   MUTAGEN         427
FT                   /note="F->A: Loss of interaction with ENAH and no induction
FT                   of filopodia; when associated with A-428."
FT                   /evidence="ECO:0000269|PubMed:11696321"
FT   MUTAGEN         428
FT                   /note="P->A: Loss of interaction with ENAH and no induction
FT                   of filopodia; when associated with A-427."
FT                   /evidence="ECO:0000269|PubMed:11696321"
FT   CONFLICT        84
FT                   /note="R -> W (in Ref. 4; BAD96390)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        415
FT                   /note="Y -> H (in Ref. 4; BAD96390)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        473
FT                   /note="A -> T (in Ref. 4; BAD96390)"
FT                   /evidence="ECO:0000305"
FT   HELIX           5..22
FT                   /evidence="ECO:0007829|PDB:2YKT"
FT   HELIX           24..64
FT                   /evidence="ECO:0007829|PDB:2YKT"
FT   STRAND          66..68
FT                   /evidence="ECO:0007829|PDB:2YKT"
FT   HELIX           70..98
FT                   /evidence="ECO:0007829|PDB:2YKT"
FT   TURN            99..101
FT                   /evidence="ECO:0007829|PDB:2YKT"
FT   HELIX           102..146
FT                   /evidence="ECO:0007829|PDB:2YKT"
FT   HELIX           150..152
FT                   /evidence="ECO:0007829|PDB:1WDZ"
FT   TURN            154..157
FT                   /evidence="ECO:0007829|PDB:1Y2O"
FT   HELIX           159..228
FT                   /evidence="ECO:0007829|PDB:2YKT"
FT   HELIX           238..246
FT                   /evidence="ECO:0007829|PDB:1Y2O"
FT   HELIX           281..286
FT                   /evidence="ECO:0007829|PDB:4JS0"
FT   STRAND          378..383
FT                   /evidence="ECO:0007829|PDB:3RNJ"
FT   STRAND          401..404
FT                   /evidence="ECO:0007829|PDB:3RNJ"
FT   STRAND          406..408
FT                   /evidence="ECO:0007829|PDB:3RNJ"
FT   STRAND          413..418
FT                   /evidence="ECO:0007829|PDB:3RNJ"
FT   TURN            419..421
FT                   /evidence="ECO:0007829|PDB:3RNJ"
FT   STRAND          424..428
FT                   /evidence="ECO:0007829|PDB:3RNJ"
FT   HELIX           429..431
FT                   /evidence="ECO:0007829|PDB:3RNJ"
FT   STRAND          432..434
FT                   /evidence="ECO:0007829|PDB:3RNJ"
FT   TURN            458..460
FT                   /evidence="ECO:0007829|PDB:6ZEI"
SQ   SEQUENCE   552 AA;  60868 MW;  3B9EDC6405DCC99D CRC64;
     MSLSRSEEMH RLTENVYKTI MEQFNPSLRN FIAMGKNYEK ALAGVTYAAK GYFDALVKMG
     ELASESQGSK ELGDVLFQMA EVHRQIQNQL EEMLKSFHNE LLTQLEQKVE LDSRYLSAAL
     KKYQTEQRSK GDALDKCQAE LKKLRKKSQG SKNPQKYSDK ELQYIDAISN KQGELENYVS
     DGYKTALTEE RRRFCFLVEK QCAVAKNSAA YHSKGKELLA QKLPLWQQAC ADPSKIPERA
     VQLMQQVASN GATLPSALSA SKSNLVISDP IPGAKPLPVP PELAPFVGRM SAQESTPIMN
     GVTGPDGEDY SPWADRKAAQ PKSLSPPQSQ SKLSDSYSNT LPVRKSVTPK NSYATTENKT
     LPRSSSMAAG LERNGRMRVK AIFSHAAGDN STLLSFKEGD LITLLVPEAR DGWHYGESEK
     TKMRGWFPFS YTRVLDSDGS DRLHMSLQQG KSSSTGNLLD KDDLAIPPPD YGAASRAFPA
     QTASGFKQRP YSVAVPAFSQ GLDDYGARSM SRNPFAHVQL KPTVTNDRCD LSAQGPEGRE
     HGDGSARTLA GR
//
